# US 4,377,511 A · Preparation for control of T-system of immunity and method for producing same > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 4,377,511 A - Document ID: US4377511A - Status: Granted - Kind: A - Application number: 06/203,347 - Filed: 1980-11-03 - Granted: 1983-03-22 - Earliest claimed: 1980-11-03 - Inventors: Jury M. Lopukhin; Rem V. Petrov; Vitaly Y. Arion; Jury N. Breusov; Tatyana V. Gladysheva; Irina V. Sanina; Vasily V. Lebedev; Serafima S. Kirzon; Evgeny F. Ivanushkin - Web page: https://patentgrep.com/patent/US4377511A ## CPC - A61K 35/26: Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 35/00: Antineoplastic agents - A61P 37/00: Drugs for immunological or allergic disorders - Y10S 530/837: Lymph; lymph-glands; thymus - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS ## Abstract The present invention relates to immunopharmacology and, more specifically, to a preparation controlling the T-system of immunity and to a method for producing the same. The preparation controlling the T-system of immunity is characterized by its content as the active principle, peptides with a molecular mass of from 1,500 to 6,000 Dalton having absorption maximum in UV-light at 280 and 275 nm and electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930. The method for producing the preparation according to the present invention comprises homogenization of a tissue of thymus gland in a solution of sodium chloride; the homogenizate is kept for 12-16 hours at a temperature of from 2.degree. to 6.degree. C., the residue is removed, thermolabile proteins are removed from the solution, peptides and proteins are precipitated and then dissolved and peptides are salted-out from the solution successively in three stages, the residue of peptides is removed, ultrafiltered through a membrane with a rated retention limit relative to globular proteins of from 12,000 to 30,000, the ultrafiltrate is gel-chromatographed to isolate peptides with a molecular mass of from 1,500 to 6,000 Dalton, desalted and lyophilized. This preparation is used for the treatment of primary and secondary immunodeficient states, diseases caused by malignant neoplasms, psoriasis and other pathological states. ## Claims ### Claim 1 An active principle effective for control of the T-system of immunity, said active principle being obtained by removing thermolabile proteins from a solution of homogenized thymus gland tissue in a sodium chloride solution, precipitating proteins and peptides from the solution, dissolving the same in a solvent therefor, salting out the peptides from the solution, dissolving the peptides, subjecting the resulting solution to ultrafiltration, and subjecting the resulting ultrafiltrate to gel chromatography, and said active principle consisting of polypeptides with a molecular mass of from 1,500 to 6,000 Dalton, having the maximum of absorption in UV-light as 208 and 275 nm and the electrophoretic mobility in a polyacrylamide gel relative to bromophenol blue of: 0.062-0.102; 0.156-0.236; 0.354-0.374; 0.382-0.422; 0.432-0.472; 0.485-0.545; 0.850-0.930. ### Claim 2 (depends on 1) A preparation according to claim 1, wherein as the pharmaceutical vehicle a physiological solution is used. ### Claim 3 (depends on 2) A preparation according to claim 2, wherein the physiological solution is a 0.14 M NaCl solution. ### Claim 4 (depends on 1) A preparation according to claim 1, wherein the content of the active principle is about 100 to 200 .mu.g/ml for injections. ### Claim 5 (depends on 1) A method for producing the active principle of claim 1 for control of the T-system of immunity, which comprises: (1) homogenizing a thymus gland tissue in a sodium chloride solution; (2) keeping the homogenizate for 12 to 16 hours at a temperature of from 2.degree. to 6.degree. C.; (3) removing the residue from the homogenizate; (4) heating the remaining solution to a temperature within the range of from 70.degree. to 90.degree. C. to from a residue of thermolabile protein components; (5) removing the thermolabile proteins from the solution; (6) precipitating proteins and peptides from the solution; (7) dissolving the thus precipitated proteins and peptides in a solvent therefor; (8) salting-out the peptides from the solution in three stages, the first being conducted in a 20-30%, by saturation, solution of ammonium sulphate at a pH of from 6.9 to 7.1, the second in a 45-55%, by saturation, solution of ammonium sulphate at a pH of from 3.9 to 4.1, and the third in a 45-55%, by saturation, solution of ammonium sulphate at a pH of from 4.5 to 6.0; (9) dissolving the resulting residue of peptides; (10) subjecting the formed solution to ultrafiltration through a membrane with a rated retention limit relative to globular proteins of from 12,000 to 30,000 Dalton; (11) subjecting the obtained ultrafiltrate to gel-chromatography to separate the peptides with a molecular mass of from 1,500 to 6,000 Dalton in a buffer solution at a pH of from 6.8 to 8.2 and an ionic strength of from 0.1 to 0.4 M; (12) desalting the separated peptides and subjecting the same to lyophilization. ### Claim 6 (depends on 5) The method for producing the active principle according to claim 5, wherein salting-out at the stage (8) is effected at a concentration of proteins and peptides in the solution of from 15 to 25 mg/ml. ### Claim 7 (depends on 5) The method for producing the active principle according to claim 5, wherein the homogenate in stage (2) is kept at the ratio between the solid and liquid portions of 1:3. ### Claim 8 (depends on 5) The method for producing the active principle according to claim 5, wherein gel-chromatography of peptides in stage (11) is effected in a buffer solution containing KCl or NaCl. ### Claim 9 (depends on 1) A preparation comprising an effective amount of the T-system immunity active principle of claim 1 and a pharmaceutical vehicle therefor.